Publications by authors named "Z Nowecki"
Article Synopsis
- The SERENA-2 trial investigates the efficacy of camizestrant, a new oral selective estrogen receptor degrader, compared to the traditional injectable SERD, fulvestrant, in treating advanced hormone receptor-positive breast cancer in post-menopausal women.
- This phase 2 trial includes patients who have experienced disease progression after previous endocrine therapies and assesses different dosages of camizestrant against fulvestrant, focusing on progression-free survival rates as the primary outcome.
- Conducted across 74 centers worldwide, the study also monitors the safety and side effects of the treatments among all participants who received at least one dose.
Article Synopsis
- * In a phase 3 trial involving 325 patients, those taking inavolisib had a median progression-free survival of 15.0 months, significantly better than the 7.3 months for the placebo group, indicating better disease management.
- * The treatment with inavolisib showed promising results with a 58.4% objective response rate; however, there were notable side effects, similar between both groups, including high rates of neutropenia
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
Guilherme Nader-Marta Christian Singer Dominik Hlauschek Angela DeMichele Paolo Tarantino Zbigniew Nowecki
Breast Cancer Res
October 2024
Article Synopsis
- The study explores how low levels of HER2 expression affect breast cancer treatment outcomes and the success of hormone therapy in patients.
- It analyzes data from a large international study called PALLAS, which included over 5,000 patients to see how HER2 status impacts survival rates and response to the drug palbociclib.
- The research found that HER2-low levels are common and vary between countries, but HER2 status didn’t significantly change the success rate of hormone therapy in the patients.
Article Synopsis
- The study investigates the presence and burden of coronary artery calcium (CAC) in cancer patients undergoing anthracycline chemotherapy, assessing cardiovascular risks associated with cancer treatment.
- A total of 80 patients were included, with most being diagnosed with breast cancer and categorized into moderate and high-risk groups for chemotherapy-related cardiovascular toxicity.
- Results showed that high-risk patients had significantly higher CAC scores, elevated cardiac biomarkers, and more common diastolic dysfunction, despite similar left ventricle ejection fractions compared to moderate-risk patients.
Article Synopsis
- - Capivasertib, a selective pan-AKT inhibitor, was shown to significantly improve progression-free survival when added to fulvestrant compared to fulvestrant alone in patients with advanced breast cancer (P < 0.001), specifically those who had previously experienced disease progression on aromatase inhibitors.
- - In a randomized trial with 708 patients, individuals received either capivasertib plus fulvestrant or a placebo plus fulvestrant, with safety analyses revealing common adverse events (AEs) like diarrhea, rash, and hyperglycemia associated with capivasertib treatment.
- - Among 705 patients analyzed, 72.4% experienced diarrhea, while 38% had a rash